Methoxylated flavones, a superior cancer chemopreventive flavonoid subclass?

Seminars in Cancer Biology

Volumn 17, Issue 5, 2007, Pages 354-362

  Walle, Thomas ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Bioavailability; Cancer prevention; Chemoprevention; Flavonoids; Methoxyflavones

Indexed keywords

AROMATASE INHIBITOR; CARCINOGEN; CYTOCHROME P450 1A1; CYTOCHROME P450 1B1; FLAVONE DERIVATIVE; FLAVONOID; METHOXYFLAVONE DERIVATIVE; NOBILETIN; POLYCYCLIC AROMATIC HYDROCARBON DERIVATIVE; POLYPHENOL DERIVATIVE; TANGERETIN; UNCLASSIFIED DRUG;

CANCER PREVENTION; CELL CYCLE REGULATION; DIETARY INTAKE; ENZYME INHIBITION; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MEMBRANE TRANSPORT; NONHUMAN; NUTRITION; PHYTONUTRIENT; REVIEW;

ANIMALS; ANTICARCINOGENIC AGENTS; CELL TRANSFORMATION, NEOPLASTIC; CHEMOPREVENTION; FLAVONES; FLAVONOIDS; HUMANS; METHYLATION; NEOPLASMS;

EID: 34548423695     PISSN: 1044579X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semcancer.2007.05.002     Document Type: Review

References (79)

1. Middleton E.J., Kandaswami C., and Theoharides T.C. The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease, and cancer. Pharmacol Rev 52 (2000) 673-751
2. Yang C.S., Prabhu S., and Landau J. Prevention of carcinogenesis by tea polyphenols. Drug Metab Rev 33 (2001) 237-253
3. Pervaiz S. Resveratrol: from grapevines to mammalian biology. FASEB J 17 (2003) 1975-1985
4. Ciolino H.P., Daschner P.J., Wang T.T.Y., and Yeh G.C. Effect of curcumin on the aryl hydrocarbon receptor and cytochrome P450 1A1 in MCF-7 human breast carcinoma cells. Biochem Pharmacol 56 (1998) 197-206
5. Ciolino H.P., Daschner P.J., and Yeh G.C. Dietary flavonols quercetin and kaempferol are ligands of the aryl hydrocarbon receptor that affect CYP1A1 transcription differentially. Biochem J 340 (1999) 715-722
6. Ciolino H.P., and Yeh G.C. Inhibition of aryl hydrocarbon-induced cytochrome P450 1A1 enzyme activity and CYP1A1 expression by resveratrol. Mol Pharmacol 56 (1999) 760-767
7. Fang J., Xia C., Cao Z., Zheng J.Z., Reed E., and Jiang B.-H. Apigenin inhibits VEGF and HIF-1 expression via PI3K/AKT/p70S6K1 and HDM2/p53 pathways. FASEB J 19 (2005) 342-353
8. Choi H., Chun Y.-S., Kim S.-W., Kim M.-S., and Park J.-W. Curcumin inhibits hypoxia-inducible factor-1 by degrading aryl hydrocarbon receptor nuclear translocator: a mechanism of tumor growth inhibition. Mol Pharmacol 70 (2006) 1664-1671
9. Hou Z., Sang S., You H., Lee M.-J., Hong J., Chin K.-V., et al. Mechanism of action of (-)-epigallocatechin-3-gallate: auto-oxidation-dependent inactivation of epidermal growth factor receptor and direct effects on growth inhibition in human esophageal cancer KYSE 150 cells. Cancer Res 65 (2005) 8049-8056
10. Lu J., Papp L.V., Fang J., Rodriguez-Nieto S., Zhivotovsky B., and Holmgren A. Inhibition of mammalian thioredoxin reductase by some flavonoids: implications for myricetin and quercetin anticancer activity. Cancer Res 66 (2006) 4410-4418
11. Haghiac M., and Walle T. Quercetin induces necrosis and apoptosis in the SCC-9 oral cancer cells. Nutr Cancer 53 (2005) 220-231
12. Li M., Zhang Z., Hill D.L., Wang H., and Zhang R. Curcumin, a dietary component, has anticancer, chemosensitization, and radiosensitization effects by down-regulating the MDM2 oncogene through the PI3K/mTOR/ETS2 pathway. Cancer Res 67 (2007) 1988-1996
13. Ermakova S.P., Kang B.S., Choi B.Y., Choi H.S., Schuster T.F., Ma W.-Y., et al. (-)-Epigallocatechin gallate overcomes resistance to etoposide-induced cell death by targeting the molecular chaperone glucose-regulated protein 78. Cancer Res 66 (2006) 9260-9268
14. Walle T., Otake Y., Brubaker J.A., Walle U.K., and Halushka P.V. Disposition and metabolism of the flavonoid chrysin in normal volunteers. Br J Clin Pharmacol 51 (2001) 143-146
15. Manach C., and Donovan J.L. Pharmacokinetics and metabolism of dietary flavonoids in humans. Free Radic Res 38 (2004) 771-785
16. Garcea G., Jones D.J., Singh R., Dennison A.R., Farmer P.B., Sharma R.A., et al. Detection of curcumin and its metabolites in hepatic tissue and portal blood of patients following oral administration. Br J Cancer 90 (2004) 1011-1015
17. Goldberg D.M., Yan J., and Soleas G.J. Absorption of three wine-related polyphenols in three different matrices by healthy subjects. Clin Biochem 36 (2003) 79-87
18. Walle T., Hsieh F., DeLegge M.H., Oatis J.E.J., and Walle U.K. High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab Dispos 32 (2004) 1377-1382
19. Chow H.H.S., Cai Y., Alberts D.S., Hakim I., Dorr R., Shahi F., et al. Phase I pharmacokinetic study of tea polyphenols following single-dose administration of epigallocatechin gallate and polyphenol E. Cancer Epidemiol Biomarkers Prev 10 (2001) 53-58
20. Warden B.A., Smith L.S., Beecher G.R., Balentine D.A., and Clevidence B.A. Catechins are bioavailable in men and women drinking black tea throughout the day. J Nutr 131 (2001) 1731-1737
21. Lambert J.D., Hong J., Yang G., Liao J., and Yang C.S. Inhibition of carcinogenesis by polyphenols: evidence from laboratory investigations. Am J Clin Nutr (Suppl) 81 (2005) 284S-291S
22. Izumi T., Piskula M.K., Osawa S., et al. Soy isoflavone aglycones are absorbed faster and in higher amounts than their glucosides in humans. J Nutr 130 (2000) 1695-1699
23. Ju Y.H., Allred C.D., Allred K.F., Karko K.L., Doerge D.R., and Helferich W.G. Physiological concentrations of dietary genistein dose-dependently stimulate growth of estrogen-dependent human breast cancer (MCF-7) tumors implanted in athymic nude mice. J Nutr 131 (2001) 2957-2962
24. Kano M., Takayanagi T., Harada K., Sawada S., and Ishikawa F. Bioavailability of isoflavones after ingestion of soy beverages in healthy adults. J Nutr 136 (2006) 2291-2296
25. Tsuji P.A., and Walle T. Inhibition of benzo[a]pyrene-activating enzymes and DNA-binding in human bronchial epithelial BEAS-2B cells by methoxylated flavonoids. Carcinogenesis 27 (2006) 1579-1585
26. Otake Y., Hsieh F., and Walle T. Glucuronidation versus oxidation of the flavonoid galangin by human liver microsomes and hepatocytes. Drug Metab Dispos 30 (2002) 576-581
27. Wen X., and Walle T. Methylation protects dietary flavonoids from rapid hepatic metabolism. Xenobiotica 36 (2006) 387-397
28. Wen X., and Walle T. Methylated flavonoids have greatly improved intestinal absorption and metabolic stability. Drug Metab Dispos 34 (2006) 1786-1792
29. Artursson P. Cell cultures as models for drug absorption across the intestinal mucosa. Crit Rev Ther Drug Carr Syst 8 (1991) 305-330
30. Artursson P., and Karlsson J. Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem Biophys Res Commun 175 (1991) 880-885
31. Walle T., Ta N., Kawamori T., Wen X., Tsuji P.A., and Walle U.K. Cancer chemopreventive properties of orally bioavailable flavonoids-methylated versus unmethylated flavones. Biochem Pharmacol 73 (2007) 1288-1296
32. Walle U.K., Galijatovic A., and Walle T. Transport of the flavonoid chrysin and its conjugated metabolites by the human intestinal cell line Caco-2. Biochem Pharmacol 58 (1999) 431-438
33. Tsuji P.A., Winn R.N., and Walle T. Accumulation and metabolism of the anticancer flavonoid 5,7-dimethoxyflavone compared to its unmethylated analog chrysin in the Atlantic killifish. Chem-Biol Interact 164 (2006) 85-92
34. Murakami A., Koshimizu K., Ohigashhi H., Kuwahara S., Kuki W., Takahashi Y., et al. Characteristic rat tissue accumulation of nobiletin, a chemopreventive polymethoxyflavonoid, in comparison with luteolin. BioFactors 16 (2002) 73-82
35. Kurowska E.M., and Manthey J.A. Hypolipidemic effects and absorption of citrus polymethoxylated flavones in hamsters with diet-induced hypercholesterolemia. J Agric Food Chem 52 (2004) 2879-2886
36. Hecht S.S. Cigarette smoking and lung cancer: chemical mechanisms and approaches to prevention. Lancet Oncol 3 (2002) 461-469
37. Wen X., Walle U.K., and Walle T. 5,7-Dimethoxyflavone down-regulates CYP1A1 expression and benzo[a]pyrene-induced DNA binding in Hep G2 cells. Carcinogenesis 26 (2005) 803-809
38. Wen X., and Walle T. Preferential induction of CYP1B1 by benzo[a]pyrene in human oral epithelial cells: impact on DNA adduct formation and prevention by polyphenols. Carcinogenesis 26 (2005) 1774-1781
39. Wen X., and Walle T. Cytochrome P450 1B1, a biomarker and chemopreventive target for benzo[a]pyrene-initiated human esophageal cancer. Cancer Lett 246 (2006) 109-114
40. Lee J.-E., and Safe S. 3′,4′-Dimethoxyflavone as an aryl hydrocarbon receptor antagonist in human breast cancer cells. Toxicol Sci 58 (2000) 235-242
41. Walle T, Walle UK. Novel methoxylated flavone inhibitors of cytochrome P450 1B1 in SCC-9 human oral cancer cells. J Pharm Pharmacol; in press.
42. Zhang S., Qin C., and Safe S. Flavonoids as aryl hydrocarbon receptor agonists/antagonists: effects of structure and cell context. Environ Health Perspect 111 (2003) 1877-1882
43. Harper P.A., Riddick D.S., and Okey A.B. Regulating the regulator: factors that control levels and activity of the aryl hydrocarbon receptor. Biochem Pharmacol 72 (2006) 267-279
44. Palermo C.M., Westlake C.A., and Gasiewicz T.A. Epigallocatechin gallate inhibits aryl hydrocarbon receptor gene transcription through an indirect mechanism involving binding to a 90 kDa heat shock protein. Biochemistry 44 (2005) 5041-5052
45. Lee J.-E., and Safe S. Involvement of a post-transcriptional mechanism in the inhibition of CYP1A1 expression by resveratrol in breast cancer cells. Biochem Pharmacol 62 (2001) 1113-1124
46. Manthey J.A., Guthrie N., and Grohmann K. Biological properties of citrus flavonoids pertaining to cancer and inflammation. Curr Med Chem 8 (2001) 135-153
47. Manthey J.A., and Guthrie N. Antiproliferative activities of citrus flavonoids against six human cancer cell lines. J Agric Food Chem 50 (2002) 5837-5843
48. Williams R.J., Spencer J.P.E., and Rice-Evans C. Flavonoids: antioxidants and signalling molecules?. Free Radic Biol Med 36 (2004) 838-849
49. Chiang L.-C., Ng L.T., Lin I.-C., Kuo P.-L., and Lin C.-C. Anti-proliferative effect of apigenin and its apoptotic induction in Hep G2 cells. Cancer Lett 237 (2006) 207-214
50. Trochon V., Blot E., Cymbalista F., Engelmann C., Tang R.P., Thomaidis A., et al. Apigenin inhibits endothelial-cell proliferation in G(2)/M phase whereas it stimulates smooth-muscle cells by inhibiting P21 and P27 expression. Int J Cancer 85 (2000) 691-696
51. Ujiki M.B., Ding X.-Z., Salabat M.R., Bentrem D.J., Golkar L., Milam B., et al. Apigenin inhibits pancreatic cancer cell proliferation through G2/M cell cycle arrest. Mol Cancer 5 (2006) 1-8
52. Pouget C., Lauthier F., Simon A., Fagnere C., Basly J.-P., Delage C., et al. Flavonoids: structural requirements for antiproliferative activity on breast cancer cells. Bioorg Med Chem Lett 11 (2001) 3095-3097
53. Stoner G., Kaighn M., Reddel R., Resau J., Bowman D., Naito Z., et al. Establishment and characterization of SV40 T-antigen immortalized human esophageal epithelial cells. Cancer Res 51 (1991) 365-371
54. Reddel R.R., Ke Y., Gerwin B.I., McMenamin M.G., Lechner J.F., Su R.T., et al. Transformation of human bronchial epithelial cells by infection with SV40 or adenovirus-12 SV40 hybrid virus, or transfection via strontium phosphate coprecipitation with a plasmid containing SV40 early region genes. Cancer Res 48 (1988) 1904-1909
55. 1 phase cell cycle progression by controlling aryl hydrocarbon receptor activity. Mol Pharmacol 65 (2004) 461-469
56. Bock K.W., and Köhle C. Ah receptor- and TCDD-mediated liver tumor promotion: clonal selection and expansion of cells evading growth arrest and apoptosis. Biochem Pharmacol 69 (2005) 1403-1408
57. Ta N, Walle T. Aromatase inhibition by bioavailable methylated flavones. J Steroid Biochem Mol Biol; in press.
58. Kao Y.-C., Zhou C., Sherman M., Laughton C.A., and Chen S. Molecular basis of the inhibition of human aromatase (estrogen synthetase) by flavone and isoflavone phytoestrogens: a site-directed mutagenesis study. Environ Health Perspect 106 (1998) 85-92
59. Pan M.-H., Chen W.-J., Lin-Shiau S.-Y., Ho C.-T., and Line J.-K. Tangeretin induces cell-cycle G1 arrest through inhibiting cyclin-dependent kinases 2 and 4 activities as well as elevating Cdk inhibitors p21 and p27 in human colorectal carcinoma cells. Carcinogenesis 23 (2002) 1677-1684
60. Chen K.-H., Weng M.-S., and Lin J.-K. Tangeretin suppresses IL-1β-induced cyclooxygenase (COX)-2 expression through inhibition of p38 MAPK, JNK, and AKT activation in human lung carcinoma cells. Biochem Pharmacol 73 (2007) 215-227
61. Van Slambrouck S., Parmar V.S., Sharma S.K., De Bondt B., Foré F., Coopman P., et al. Tangeretin inhibits extracellular-signal-regulated kinase (ERK) phosphorylation. FEBS Lett 579 (2005) 1665-1669
62. Morley K.L., Ferguson P.J., and Koropatnick J. Tangeretin and nobiletin induce G1 cell cycle arrest but not apoptosis in human breast and colon cancer cells. Cancer Lett 251 (2007) 168-178
63. Hirano T., Abe K., Gotoh M., and Oka K. Citrus flavone tangeretin inhibits leukaemic HL-60 cell growth partially through induction of apoptosis with less cytotoxicity on normal lymphocytes. Br J Cancer 72 (1995) 1380-1388
64. Murakami A., Nakamura Y., Torikai K., Tanaka T., Koshiba T., Koshimizu K., et al. Inhibitory effect of citrus nobiletin on phorbol ester-induced skin inflammation, oxidative stress, and tumor promotion in mice. Cancer Res 60 (2000) 5059-5066
65. Tang M., Ogawa K., Asamoto M., Hokaiwado N., Seeni A., Suzuki S., et al. Protective effects of citrus nobiletin and auraptene in transgenic rats developing adenocarcinoma of the prostate (TRAP) and human prostate carcinoma cells. Cancer Sci 98 (2007) 471-477
66. Sato T., Koike L., Miyata Y., Hirata M., Mimaki Y., Sashida Y., et al. Inhibition of activator protein-1 binding activity and phosphatidylinositol 3-kinase pathway by nobiletin, a polymethoxy flavonoid, results in augmentation of tissue inhibitor of metalloproteinases-1 production and suppression of production of matrix metalloproteinases-1 and -9 in human fibrosarcoma HT-1080 cells. Cancer Res 62 (2002) 1025-1029
67. Kawabata K., Murakami A., and Ohigashi H. Nobiletin, a citrus flavonoid, down-regulates matrix metalloproteinase-7 (matrilysin) expression in HT-29 human colorectal cancer cells. Biosci Biotechnol Biochem 69 (2005) 307-314
68. Minagawa A., Otani Y., Kubota T., Wada N., Furukawa T., Kumai K., et al. The citrus flavonoid, nobiletin, inhibits peritoneal dissemination of human gastric carcinoma in SCID mice. Jpn J Cancer Res 92 (2001) 1322-1328
69. Lu Y., Zhang C., Bucheli P., and Wei D. Citrus flavonoids in fruit and traditional Chinese medicinal food ingredients in China. Plant Foods Hum Nutr 61 (2006) 57-65
70. Nogata Y., Sakamoto K., Shiratsuchi H., Ishii T., Yano M., and Ohta H. Flavonoid composition of fruit tissues of citrus species. Biosci Biotechnol Biochem 70 (2006) 178-192
71. Mizuno M., Iinuma M., Ohara M., Tanaka T., and Iwamasa M. Chemotaxonomy of the genus Citrus based on polymethoxyflavones. Chem Pharm Bull 39 (1991) 945-949
72. Jaipetch T., Reutrakul V., Tuntiwachwuttikul P., and Santisuk T. Flavonoids in the black rhizomes of Boesenbergia pandurata. Phytochemistry 22 (1983) 625-626
73. Yenjai C., Prasanphen K., Daodee S., Wongpanich V., and Kittakoop P. Bioactive flavonoids from Kaempferia parviflora. Fitoterapia 75 (2004) 89-92
74. Cavalcante S.H., Fernandes D., Paulino Fo H.F., Yoshida M., and Gottlieb O.R. Lignoids from the fruit of three Virola species. Phytochemistry 24 (1985) 1865-1866
75. Santos L.S., Corréa M.J.C., Campos L.M.O., and Andrade M.A. Constituents from the leaves of Virola michelli. Fitoterapia 67 (1996) 555-556
76. Popravko S.A., Gurevich A.I., and Kolosov M.N. Flavonoid components of propolis. Khimiya Prirodnykh Soedinenii 5 (1969) 476-482
77. Ahmad F., Bakar S.A., Ibrahim A.Z., and Read R.W. Constituents of the leaves of Piper caninum. Planta Med 63 (1997) 193-194
78. Maserejian N.N., Giovannucci E., Rosner B., Zavras A., and Joshipura K. Prospective study of fruits and vegetables and risk of oral premalignant lesions in men. Am J Epidemiol 164 (2006) 556-566
79. Stoner G. Introduction. Nutr Cancer 54 (2006) 1-2